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The effect of hyperbaric oxygen treatment (HBOT) was examined using MSG mice, which are an
animal model of obesity, hyperlipidemia, diabetes, and nonalcoholic fatty liver disease. Nineteen
MSG male mice were divided into HBOT treated and control groups at 12 weeks of ages. The
HBOT group was treated with hyperbaric oxygen from 12 to 14 weeks (ﬁrst phase) and then
from 16 to 18 weeks (second phase). Interestingly, the body weight of the HBOT group was
signiﬁcantly lower (P < 0.01) than that of the control group. In contrast, the serum lipid level did
not show signiﬁcant changes between the two groups. As for the effects of increasing oxidative
stress, the liver histology of the HBOT group showed severer cellular damage and aberrant TNF-α
expression. HBOT has the advantage of improving obesity in patients with metabolic syndrome,
but the fault of causing organ damage by increasing oxidative stress.
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1. INTRODUCTION
“Metabolic syndrome” is serious current issue. Metabolic syndrome is called “visceral fat syndrome”
because visceral fat accumulation and macrophage aggregations described as “crown-like structures” occur
primarily and then cause various intractable disorders to the whole body [1, 2]. The liver phenotype of
metabolic syndrome is called “nonalcoholic fatty liver disease (NAFLD)” and nonalcoholic steatohepatitis
(NASH), which is the critical type of NAFLD, is a refractory progressive disease, which progresses
to liver cirrhosis or hepatocellular carcinoma [3–5]. Although the elucidation of the mechanism behind
the pathological condition remains controversial, the “two-hit theory” has support as the pathogenetic
mechanism of NASH. It is suggested that simple steatosis arises as a result of the ﬁr s th i ta n dt h a tt h e
pathologic condition progresses due to a second hit such as oxidative stress [6]. This means that oxidative
stress may be an exacerbating factor of liver disease caused by metabolic syndrome.
Hyperbaric oxygen therapy (HBOT) is a remedy in which an atmospheric pressure environment
higher than the normal atmosphere is created artiﬁcially, and the patient inhales hyperbaric oxygen
continuously in the environment in order to increase the level of dissolved oxygen in their blood, which
promptly acts to improve systemic or local hypoxia [7]. This remedy is usually employed for conditions
such as carbon monoxide poisoning, limb arterial occlusive diseases, diseases of the central nervous system,
sudden deafness,and retinal arterial occlusion. Recently, its application has been expandedto multipleﬁelds
including orthopedics [8, 9] and sports medicine [10, 11]. We have proposed the possibility that HBOT
would be effective in the treatment of autoimmune diseases and hematopoietic malignancies [12, 13]. These
effects are supposedly caused by the strong oxidative stress that is produced as a side effect of HBOT. We
hypothesized that oxidative stress predominantly affects autoreactive lymphoid and tumor cells. Various
inﬂammatory cytokines play an important role in the onset and progression of metabolic syndrome and
NASH [14]. The visceral fat cells of obese patients store several times more fat than those of nonobese
patients. These cells are often enlarged, and their cell membranes frequently collapse causing the leakage
of stored lipids. Subsequently, macrophages begin to cluster in order to process these lipids. These clustered
macrophages are called “crown-like structures” and are frequently observed in the visceral fat of patients
with metabolic syndrome [15, 16]. It is thought that the various cytokines and chemokines that are produced
by these macrophages in visceral fat are closely related to the onset and exacerbation of the symptoms of
metabolic syndrome. They are also considered to be involved in the formation of hepatic lesions through
the portal vein. It is expected that when HBOT is used for the treatment of metabolic syndrome [17–19],
these excessively activated cytokines may be inhibited, at the same time, as metabolism is accelerated by
t h em o r ee f ﬁcient oxygen supply. On the other hand, the risk that NASH will be worsened by increased
oxidative stress is also taken into consideration [20–22]. In this study, using MSG mice with NASH and a
background of obesity, hyperlipidemia, and type-2 diabetes which are all symptoms of metabolic syndrome,
the effects of HBOT on obesity, hyperlipidemia, and NASH are examined [23, 24].
2. MATERIALS AND METHODS
2.1. Experimental Animals
The MSG mouse is an obese animal model, which is prepared by hypodermic injection of monosodium
glutamate (MSG) into an ICR mouse immediately after birth. This mouse is reported to show symptoms of
obesity, type-2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease after usual feeding without
showing hyperphagia [23, 24]. Although it is known that MSG mice of both sexes demonstrate various
symptoms of metabolic syndrome, males show more severe symptoms. MSG mice are usually prepared
by administering a hypodermic injection of MSG of 2mg per g of body weight for successive ﬁve days.
Recently, Sasaki et al. reported that MSG mice that were prepared by one hypodermic injection of 4mg
MSG showed a more severe pathologic condition than those produced using the conventional method [25].
In present study, 19 MSG male mice were prepared according to the method of Sasaki et al.
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2.2. Study Design
Nineteen MSG male mice were divided into the HBOT-treated group (n = 10) and the control group
(HBOT-untreated group) (n = 9) at 12 weeks of age. The HBOT-treated group was treated with HBOT
(2.5ATA/60min/d) over 2 weeks from 12 to 14 weeks of age for 1 hour a day (ﬁrst phase). Then, after a
two-week interval, the mice were treated with HBOT (2.5ATA/60min/d) for another two weeks from 16 to
18 weeks of ages for 1 hour a day (second phase). The control group was kept in a chamber under normal
pressure instead of HBOT for 1 hour and supplied with a normal concentration of oxygen. The mice in each
group were sacriﬁced after 12 hours of fasting after the last HBOT treatment, and their serum, liver, and
visceral fat were extracted.
2.3. Measured Parameters
Weekly weight was measured from the start of the experiment until sacriﬁce. In serum, triglycerides (TG),
total cholesterol (T-chol), very-low-density lipoprotein (VLDL-) chol, low-density lipoprotein (LDL-) chol,
and high-density lipoprotein cholesterol (HDL-) chol were measured. The cholesterol and phospholipid
proﬁles in serum lipoproteins were analyzed using a dual-detection HPLC system with two tandem-
connected TSKgel LipopropakXL columns (300mm × 7.8mm; Tosoh, Tokyo, Japan) at Skylight Biotech
(Akita, Japan).
Formalin-ﬁxed parafﬁn-embedded specimens of the visceral fat and liver were prepared and
analyzed pathomorphologically. Histopathological ﬁndings of the liver were scored using the NASH
Clinical Research Network Scoring System based on four semiquantitative factors: steatosis [0–3], lobular
inﬂammation [0–3], hepatocyte ballooning [0–2], and ﬁbrosis [0–4] as previously described [26]. The
NAFLD activity score (NAS) was deﬁned as the unweighted sum of the scores for steatosis, lobular
inﬂammation, and hepatocyte ballooning; thus, the scores ranged from 0 to 8. A NAS of 0 to 2 was
considered not diagnostic of steatohepatitis, and scores of 5 or greater were taken as diagnostic of
steatohepatitis.
2.4. Immunohistochemistry
Five μm-thick specimens from each sample were immunostained using standard immunostaining
procedures. Rat monoclonal antibody against mouse MAC-2 (Galectin-3) (Cedarlane, Hornby, Ontario;
1:100 dilutions) was used as a marker of macrophages. Rabbit polyclonal antibody against mouse TNF-
α (Monosan, Uden, The Netherlands; 1:20 dilutions) was also used. Histoﬁne-peroxidase for rat primary
antibody (Nichirei, Tokyo, Japan) and Envision-peroxidase (Envision-PO) (DAKO, Glostrup, Denmark)
for rabbit primary antibodies were used as secondary antibodies. For the substrate peroxidase, 3,3 -
diaminobenzidine (DAB) was applied. In all cases, optimal dilutions were used, and positive and negative
samples were included in each assay.
2.5. Statistical Analysis
Statistical analysis was performed with Stat View version 5.0 (Abacus Concept, Berkley, Calif, USA). Data
were expressed as mean ± SE. The differences between the control and HBOT groups were analyzed using
the Student’s t-test. A value of P < 0.05 was considered statistically signiﬁcant.
3. RESULTS
3.1. Change of Weight
The body weights of the male MSG mice prepared using a single subcutaneous injection of MSG at a dose
of 4mg per g body weight increased constantly until 20 weeks of age and then plateaued until 28 weeks
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FIGURE 2: The weight of the HBOT group was signiﬁcantly decreased compared with that in the control
group (Student’s t-test, ∗∗P < 0.01).
of age. Between 12 and 18 weeks of age, the rate of weight gain hits its peak with a mean of about a 9g
increase in weight. The changes in body weight in this study are shown in Figure 1. In the control group,
the mean weight was 56.0g at 12 weeks old, 59.2g at 14 weeks old, 61.8g at 16 weeks old, and 64.5g
at 18 weeks old, showing a constant increase. On the other hand, in the HBOT-treated group, the mean
weight was 56.8g at 12 weeks old but decreased rapidly to 53.6g at 14 weeks old, that is, immediately
after completing the ﬁrst phase of HBOT. The mean weight increased again in the period of HBOT pause,
and the mean weight was 57.9g at 16 weeks old; however, it was 51.7g at 18 weeks old, which is after the
second phase of HBOT. The weight of the HBOT group was signiﬁcantly decreased compared with that in
the control group (Figure 2).
3.2. Serum Lipid
The serum lipid levels of each group are shown in Table 1 and Figure 3. In the control group, TG was
49.3mg/dL, T-chol was 192.9mg/dL, VLDL-chol was 8.7mg/dL, LDL-chol was 41.5mg/dL, and HDL-
Chol was 142.7mg/dL. On the other hand, in the HBOT-treated group, TG increased to 61.6mg/dL.
Although T-Chol declined slightly to 175.1mg/dL, VLDL-chol was 7.4mg/dL, LDL-chol was 45.1mg/dL,
and HDL-chol was 121.7mg/dL. Although there were no statistical differences between the groups, LDL-
chol was higher and HDL-chol was lower in the HBOT-treated group.
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TABLE 1: The serum lipid.
Cholesterol (mg/dL) TG (mg/dL)
Sample Total CM
(>80nm)
VLDL
(30–80nm)
LDL
(16–30nm)
HDL
(8–16nm) Total CM
(>80nm)
VLDL
(70–80nm)
LDL
(16–30nm)
HDL
(8–16nm)
HBOT-1 217.70 3.06 15.48 52.19 146.98 165.50 27.59 84.87 19.04 34.00
HBOT-2 155.22 0.53 4.36 26.41 123.92 36.12 2.95 17.80 10.21 5.16
HBOT-3 111.52 1.05 6.32 15.74 88.41 51.20 6.58 27.34 9.82 7.47
HBOT-4 107.11 1.13 9.94 13.90 82.14 90.72 9.38 59.87 13.56 7.90
HBOT-5 166.60 0.88 11.72 37.44 116.56 78.42 5.79 49.83 15.12 7.67
HBOT-6 205.66 0.39 3.28 66.57 135.42 24.46 1.44 9.68 7.69 5.64
HBOT-7 207.75 0.25 3.72 59.95 143.82 22.55 0.86 9.86 7.63 4.20
HBOT-8 193.78 0.43 3.82 57.63 131.90 21.62 0.74 9.65 6.40 4.84
HBOT-9 245.03 1.73 9.21 98.57 135.53 71.69 12.76 36.07 12.66 10.20
HBOT-10 140.91 0.40 5.65 22.38 112.48 53.57 3.08 30.37 14.58 5.54
Ave 175.13 0.99 7.35 45.08 121.72 61.59 7.12 33.53 11.67 9.26
Cont-1 166.30 0.19 15.56 34.86 115.69 63.74 1.82 49.69 8.31 3.92
Cont-2 128.11 0.03 3.61 24.80 99.67 28.63 0.36 18.14 6.81 3.32
Cont-3 324.08 0.03 10.41 94.72 218.93 86.88 0.58 60.97 16.51 8.82
Cont-4 189.40 0.04 7.25 32.47 149.63 52.36 0.39 34.64 11.99 5.34
Cont-5 133.15 0.05 6.09 20.81 106.20 35.94 0.46 26.42 5.94 3.13
Cont-6 165.41 0.14 10.74 33.28 121.25 40.28 0.80 28.52 8.25 2.72
Cont-7 193.70 0.03 3.93 50.60 139.13 33.99 0.00 14.84 8.96 10.19
Cont-8 183.32 0.02 7.60 34.33 141.38 37.74 0.03 25.99 7.88 3.84
Cont-9 252.71 0.11 13.02 47.22 192.36 64.42 0.93 49.29 10.44 3.76
Ave 192.91 0.07 8.69 41.45 142.69 49.33 0.60 34.28 9.45 5.00
3.3. Histopathological Imaging of Visceral Fat
In the control group, visceral fat was markedly enlarged, and crown-like structures were also observed in
some places (Figure 4(a)). These represented MAC-2-positive macrophage aggregation (Figure 4(b)). On
the other hand, in the HBOT-treated group, the lipid droplets were smaller, and the number of crown-like
structures tended to be lower (Figures 4(c) and 4(d)).
3.4. Histopathological Imaging of the Liver
In the control group, fatty changes were recognized in the hepatocytes in the Zone3 to Zone2 regions.
Ballooning degeneration was also found in various locations (Figure 5(a)). TNF-α expression was not seen
in hepatocytes or Kupffer cells (Figure 5(b)). Although the emergence of lipogranuloma and focal necrosis
was also observed and the image was considered to be equivalent to human NASH, no Mallory bodies or
megamitochondria were evident and no ﬁbrosis was seen either. On the other hand, in the HBOT-treated
group, although the level of fatty change was slightly decreased compared with that in the control group,
the ballooning degeneration of hepatocytes was more intensive and appeared extensively. Mallory bodies
and the condensation of subcellular organelles were also sporadically observed (Figure 5(c) and its inset)
as were small necrotic foci. No ﬁbrosis was evident. In several cases, TNF-α expression was aberrantly
observed in the hepatocytes of the perivenular and periportal areas; however, it was not seen in Kupffer
cells (Figure 5(d)). Evaluation of liver pathology is shown in Table 2.
4. DISCUSSION
Metabolic syndrome is a combination of disorders that increase the risk of developing cardiovascular
disease and diabetes [1, 2]. It affects one in ﬁve people, and its prevalence increases with age. Some
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FIGURE 3: The serum lipid levels of each group (Student’s t-test).
studies have estimated its prevalence in the USA to be up to 25% of the population. Metabolic syndrome
is also known as metabolic syndrome X, insulin resistance syndrome, and visceral fat syndrome. Usually
it involves the development of visceral fat, after which the adipocytes (fat cells) of the visceral fat increase
the plasma levels of TNF-α and alter the levels of a number of other substances (e.g., adiponectin, resistin,
PAI-1). TNF-α has been shown not only to cause the production of inﬂammatory cytokines but also to
trigger cell signaling by interacting with the TNF-α receptor, which may lead to insulin resistance. The
progression from visceral fat to increased TNF-α to insulin resistance has some parallels to the human
development of metabolic syndrome [26, 27]. NASH is thought to be the phenotype of metabolic syndrome
in the liver, and the number of patients with the condition is constantly increasing. In Japan, 10–30% of
population is considered to have NAFLD accompanied by metabolic syndrome, and 10% is presumed
to have NASH, a progressive pathologic lesion [5]. Although there are many unclear points about the
pathogenetic mechanism of NASH, a two-hit theory in which fat is ﬁrst accumulated in hepatocytes by
overeating, hyperlipidemia, and so forth, then the pathologic condition is induced to progress by a second
hit, such as oxidative stress, is widely accepted [4, 6]. No deﬁnite remedy for metabolic syndrome or NASH
has been established, and dietary counseling and therapeutic exercise are considered as the ﬁrst options
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FIGURE 4: (a), (b) Visceral fat of control group. Adipocytes are markedly enlarged. Crown-like structures
are frequently observed (arrows) (×200) ((a) H and E staining, (b) Mac-2 immunostaining as a macrophage
marker) (c), (d) Visceral fat of HBOT group. Adipocytes are relatively small. Crown-like structures are rarely
observed (arrows). (×200) ((c) H and E staining, (d) Mac-2 immunostaining as a macrophage marker).
[28, 29]. However, a continuous strict adaptation is difﬁcult with remedies based on lifestyle improvement,
and the response rate is not always high. Large-scale clinical trials of pioglitazone for patients with NASH
caused by metabolic syndrome have been performed; however, the reported effects are contradictory. For
example, simultaneous weight gains together with improvements in damage have been reported [30–32].
Hyperbaric oxygen therapy is a remedy that improves hypoxia by inhaling hyperbaric oxygen in an
environment in which the atmospheric pressure is higher than that of the normal atmosphere. Although
it is widespread as a remedy for carbon monoxide poisoning and sudden deafness, its application for
other purposes, such as in the ﬁelds of orthopedics and sports medicine, is also being widely investigated
[7–11]. We have reported that the oxidative stress raising effects of HBOT may affect the “pathogenic
cells” involved in autoimmune disease or hematopoietic malignancies selectively, using animal models and
cultured cells [12, 13]. This indicates the potential of HBOT being applied to various diseases through a
mechanism other than medication. In this study, we proposed the hypothesis that HBOT improves various
symptoms of metabolic syndrome and attempted in vivo veriﬁcation in an animal model. The animal
model used was the MSG mouse, which shows various symptoms of metabolic syndrome with near-natural
development and is known to show the symptoms of central obesity, hyperlipidemia, type-2 diabetes, and
NASH in succession after 12 weeks of age [23, 24]. In the current study, our research was limited to obesity,
hyperlipidemia, and NASH, and the beneﬁts of HBOT on metabolic syndrome were examined.
As a result, although a weight gain of about 3g in the ﬁrst phase of the HBOT treatment period (two
weeks) was seen in the control group, weight loss was observed with eight out of ten mice in the HBOT-
treated group. The mean weight of the ten animals was 56.8g before HBOT treatment, and it decreased to
53.6g after HBOT treatment that is, a mean of 3.2g weight loss. When HBOT treatment was stopped, the
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FIGURE 5: (a), (b) Liver of the control group. (a) H and E staining, ×200 magniﬁcation. In Zone3-Zone2,
moderate fatty changes were observed. Ballooning degeneration was sporadically observed. (b) TNF-α
immunostaining, ×400 magniﬁcation. No TNF-α expression was seen in hepatocytes or Kupffer cells. (P:
portal tracts, CV: central vein) (c), (d) Liver of the HBOT group. (c) H and E staining, ×200 magniﬁcation.
Fatty changes were less severe, while marked ballooning degeneration was observed. Mallory bodies were
seen sporadically (inset). (d) TNF-α immunostaining, ×400 magniﬁcation. TNF-α expression was observed
in the hepatocytes of the perivenular and periportal areas; however, it was not seen in Kupffer cells. (P:
portal tracts, CV: central vein).
rate of weight increase of the mice recovered to the same extent as seen in the untreated mice; however, the
mean body weight among ten mice decreased from 57.9g to 51.7g (by 6.2g) during the second phase of
HBOT treatment. Although we observed the body weight reduction in the 1st phase of HBOT, the weight of
body developed slightly after two weeks of HBOT. Therefore, we performed another course of HBOT just
as what we will try in the clinics for patients with different kinds of sickness. We expected further weight
reduction to our mice, and the results were positive. However, the burst of oxidative stress might induce
normal hepatocytes but not the fat cells undergoing apoptosis. This may be consistent with our previous
experiments that cells with different origins have different threshold to oxidative stress-induced apoptosis
[13]. Furthermore, the interesting point is that cells with higher proliferative rate such as cancer cells have a
lower threshold to oxidative stress induced by hyperbaric oxygen treatment, and HBO2-induced apoptosis
of cancer cells was through the intracellular accumulation of H2O2 and O2
.− as well as the involvement
of phosphorylation of p38 MAPK [13]. Our unpublished data further demonstrated that HBO2 treatment
effectively suppressed tumor growth from lung cancer transferred SCID mice after 14 days (∗∗P < 0.01)
and 28 days (∗∗P < 0.01) of tumor transfer compared with control mice. The survival rate of HBO2
treatment mice was increased signiﬁcantly compared with control mice. Since oxidative stress is closely
related to the development and progression of metabolic syndrome and cardiovascular disease; therefore,
we should be more careful to improve this side effect: ﬁrstly, we could reduce the pressure and duration
in the 2nd phase of HBOT; secondly, supplement of optimal antioxidants could be prescribed in the 2nd
phase of HBOT. Future studies should be done in order to avoid the HBOT-mediated deterioration of liver
histology.
Although the mechanism of obesity in MSG mice is not yet clear, weight gain due to a fall in energy
consumption is suggested. In our study, it also turned out that, when MSG mice were bred with 75%
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TABLE 2: NAS score and ﬁbrosis.
Steatosis Lobular inﬂammation Hepatocyte ballooning NAS Fibrosis
HBOT-1 1 2 2 5 0
HBOT-2 1 1 1 3 0
HBOT-3 1 1 2 4 0
HBOT-4 0 1 2 3 0
HBOT-5 1 1 2 4 0
HBOT-6 1 1 1 3 0
HBOT-7 1 1 2 4 0
HBOT-8 2 1 2 5 0
HBOT-9 1 1 1 3 0
HBOT-10 2 1 1 4 0
Cont-1 1 1 1 3 0
Cont-2 2 1 1 4 0
Cont-3 1 1 0 2 0
Cont-4 2 1 1 4 1A
Cont-5 1 1 2 4 0
Cont-6 2 1 1 4 1A
Cont-7 1 1 1 3 0
Cont-8 2 1 1 4 0
Cont-9 2 1 0 3 0
of their usual food intake, the increase in weight and liver damage were identical to those seen in the
mice with normal food intakes (unpublished data). Although a future detailed examination is required for
the mechanism of weight loss induced by HBOT, one possibility is that rapid improvement in systemic
metabolism due to the sufﬁcient supply of oxygen to peripheral tissues induced the weight loss. Another
possibility is that the prevention of overactivity of pathogenic cells in visceral fat and the induction of
apoptosis cause the weight loss.
In test concerning the levels of lipid-associated molecules in serum, slight increases in triglyceride
and LDL-chol were observed in the HBOT-treated group. Since the visceral fat and fat cumulative dosage
in the liver decreased in the HBOT-treated group, the lipids may have migrated into the blood from the
cells storing them. On the other hand, although the lipid cumulative dosage in hepatocyte was decreased
in the liver, the grade of the hepatocellular damage became getting worse. While HBOT supplies sufﬁcient
oxygen to local sites, it is known to induce a strong oxidative stress. Oxidative stress is considered to be
a key accelerator of cell damage and oncogenesis as the second hit of NASH [4–6]. It was supposed that
oxidative stress also played a role in the hepatocellular damage observed in the present study. This indicates
that HBOT is a “double-edged blade” as it has the advantage of improving obesity and the fault of causing
organ damage by increasing oxidative stress.
Patients with metabolic syndrome usually have multiple diseases, and there are often many
restrictions on the medication they can take. Although HBOT has the potential of becoming an effective
remedy in support of diet restriction and therapeutic exercises, for practical use, further techniques, such
as suppressing the harmful effects of oxidative stress, are indispensable. It is believed that the intake of
antioxidants, such as polyphenol and vitamin E, is effective in reducing oxidative stress [33, 34]. It may
be possible to extract only the beneﬁts of HBOT by taking antioxidants as supplements, before and after
2132TheScientiﬁcWorldJOURNAL (2011) 11, 2124–2135
HBOT treatment. It is important to examine different conditions of HBOT treatment in order to determine
the most effective conditions for treating metabolic syndrome.
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